Clinical trials: Treatment-resistant PTSD
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Posttraumatic Stress Disorder
Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD
The goal of this clinical trial is to compare full dose MDMA-assisted therapy to placebo with therapy in participants with chronic, treatment-resistant PTSD.
- Trial name
- NCT01958593
- Testing
- Midomafetamine HCl, Psychotherapy
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Resilient Pharmaceuticals
Post Traumatic Stress Disorder
A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD
The goal of this expanded access protocol is to provide access to MDMA-assisted therapy for eligible patients with treatment-resistant PTSD who are not able to enroll in another MDMA-assisted therapy clinical trial.
- Trial name
- EAMP1 (NCT04438512)
- Testing
- Midomafetamine, Psychotherapy
- Where
- 2 sites in United States
- Sponsor
- Resilient Pharmaceuticals
Posttraumatic Stress Disorder
Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD
The goal of this clinical trial is to learn if MDMA in combination with therapy is safe and effective in people with chronic, treatment-resistant PTSD.
- Trial name
- NCT01793610
- Testing
- Comparator Dose (40mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Active Dose 1 (125 mg) MDMA HCl
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Resilient Pharmaceuticals
Posttraumatic Stress Disorder
Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial
This study will consist of a single session of MDMA-assisted therapy with a full dose of MDMA for people who took part in a study of MDMA-assisted therapy in people with posttraumatic stress disorder (PTSD) whose PTSD symptoms…
- Trial name
- NCT01458327
- Testing
- Midomafetamine, Therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Resilient Pharmaceuticals
Posttraumatic Stress Disorder
Evaluating Safety and Efficacy of Cannabis in Participants With Chronic Posttraumatic Stress Disorder
The purpose of this study is to evaluate the safety and efficacy of vaporized cannabis in participants with chronic, treatment-resistant posttraumatic stress disorder.
- Trial name
- NCT02517424
- Testing
- High THC/Low CBD Cannabis, High THC/High CBD Cannabis, Low THC/Low CBD Cannabis
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Tilray
Treatment Resistant Disorders, Post Traumatic Stress Disorder
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
Post-traumatic stress disorder (PTSD) is a complex disorder expressed as a variety of neurobiological symptoms, including anxiety, re-experiencing, hyperarousal, and avoidance symptoms, along with comorbidities such as anxiety…
- Trial name
- NCT05243329
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Halucenex Life Sciences Inc.
Posttraumatic Stress Disorder (PTSD)
Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with chronic, treatment-resistant PTSD.
- Trial name
- NCT01689740
- Testing
- Full Dose MDMA-assisted therapy (125 mg), Open-Label Full Dose MDMA-assisted therapy (125 mg), Psychotherapy
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Resilient Pharmaceuticals